Scientific Publication in Pharmaceutics

We are happy to announce that the manuscript entitled "Topical Wound Treatment with a Nitric Oxide-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice"  was accepted for publication in Pharmaceutics.

Abstract: Chronic, non-healing wounds constitute a major health problem, and the current therapeutic options are limited. Therefore, pharmaceuticals that can be locally applied to complicated wounds are urgently needed. Such treatments should directly target the underlying causes, which include diabetes mellitus, chronic local pressure and/or vascular insufficiency. A common consequence of these disorders is impaired wound angiogenesis. Here, we investigated the effect of topical application of a nitric oxide-releasing phosphodiesterase 5 inhibitor (TOP-N53)-containing liquid hydrogel on wound repair in mice. The drug-loaded hydrogel promoted re-epithelialization and angiogenesis in wounds of healthy and healing-impaired diabetic mice. Using a non-invasive label-free optoacoustic microscopy approach combined with automated vessel analysis, we show that the topical application of TOP-N53 formulation increases the microvascular network density and promotes the functionality of the newly formed blood vessels, resulting in enhanced blood perfusion of the wounds. These results demonstrate a remarkable healing-stimulating activity of topically applied TOP-N53 formulation, supporting its further development as a wound therapeutic.

Download DocumentDokument herunterladen

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juvic Inc.

Read more

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.

Read more
Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

Read more